pre-IPO PHARMA

COMPANY OVERVIEW

ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy by helping more patients fight cancer and saving lives. Its discovery engine comprises precise genome editing using CRISPR-enabled CITE, integrated circuits incorporating its PrimeR™ logic gates and therapeutic enhancements from its CARchitecture™ library, enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access.


LOCATION

  • South San Francisco, CA, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://www.arsenalbio.com/


    CAREER WEBSITE

    https://jobs.arsenalbio.com/


    SOCIAL MEDIA


    INVESTORS

    eucledean-capital ken-drazen kleiner-perkins osage-university-partners parker-institute-for-cancer-immunotherapy ucsf-foundation-investment-company westlake-village-biopartners


    PRESS RELEASES


    May 16, 2023

    ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting


    Apr 14, 2023

    ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress


    Jan 5, 2023

    ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer


    Jan 10, 2022

    ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors


    Jan 4, 2022

    ArsenalBio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference


    For More Press Releases


    Google Analytics Alternative